Download Files:
Mifamurtide (sodium)
$600 – $2,850
Products Details
Product Description
– Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research[1][2][3].
Web ID
– HY-13682B
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C59H108N6NaO19P
References
– [1]Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89.|[2]Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3.|[3]Francesca Punzo, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget. 2020 Feb 18;11(7):687-698.
CAS Number
– 90825-43-7
Molecular Weight
– 1259.48
Compound Purity
– 98.0
SMILES
– CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O[Na])=O)=O
Clinical Information
– Launched
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– NOD-like Receptor (NLR)
Isoform
– NOD2
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
